Humanigen Inc (HGENQ)

[cowtown jay]

I think we are about to blaze new frontiers of safety and efficacy across treatments of multiple indications. CMML is probably the nearest horizon, and it has not only the prospect of an expedited regulatory approval, but also the promise of a Priority Review Voucher. And of course, the biggest impact could be in using lenz as both a covid therapeutic as well as with the Novavax vaccine. And I'm very curious to see if Durrant pursues using Ifab as an ADC for Glioblastoma before CytoDyn gets too far into their program for this indication. Also, Kite/Gilead continues to be a joke, with Gilead's magrolimab failure, and Kite touting a reduction in processing time from16 days, down to 14 days, for their CAR-T, which compares to 24 hours for Gracell's new processing time. And the Class Action lawyers faulted Humanigen for not recognizing magrolimab as a viable competitive product. Gilead abandoned their magrolimab trial for lack of efficacy. That's why I told eb that I was sick and tired of looking at the Class Action suit. Lead Counsel did more to harm shareholders than the $0.047 they have settled for (which only seems to apply for about 53% of our shares, anyway).

I really think Humanigen is stronger than it has ever been, and I remain super-excited about the recall of our loaned shares.